Barnett AH, O'Gara G.Diabetes and the heart. Churchill Livingstone, London, 2003.
2.
Donnelly R.Managing cardiovascular risk in patients with diabetes. Br J Diabetes Vasc Dis2005;5:325-9.
3.
McCallum RW, Fisher M.From 4S to FIELD and PROactive: 10 years of CV trials in people with diabetes . Br J Diabetes Vasc Dis2005;5:218-25.
4.
Turner RC, Millns H., Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ1998;316:823-8.
5.
Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364:685-96.
6.
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet2000;355:253-9.
